{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T04:29:54Z","timestamp":1745468994853,"version":"3.40.4"},"reference-count":7,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2018]]},"abstract":"<jats:p>Drugs that have a good intracellular passage are used in the treatment of brucellosis. According to our knowledge, there is no report in English about rifabutin usage in brucellosis. We present a case that developed intolerance to many anti-brucella drugs, who was then successfully treated with a combination of rifabutin, ofloxacin, and ceftriaxone.<\/jats:p>","DOI":"10.1159\/000495216","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T22:01:36Z","timestamp":1551996096000},"page":"321-323","source":"Crossref","is-referenced-by-count":1,"title":["Use of Rifabutin as an Alternative Agent for Human Brucellosis: A Case Report"],"prefix":"10.1159","volume":"63","author":[{"given":"Oguz","family":"Karabay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huseyin\u00a0Dogus","family":"Okan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adem","family":"Simsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ertugrul","family":"Guclu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2019,3,7]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12351"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-4-18"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2004.05.003"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S0924-8579(99)00049-7"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a027011"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1086\/313771"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-018-0471-z"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/495216","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/495216","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T17:12:06Z","timestamp":1745428326000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000495216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":7,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,4,30]]},"published-print":{"date-parts":[[2019,5,2]]}},"URL":"https:\/\/doi.org\/10.1159\/000495216","archive":["Portico"],"relation":{},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"type":"print","value":"0009-3157"},{"type":"electronic","value":"1421-9794"}],"subject":[],"published":{"date-parts":[[2018]]}}}